Karyopharm Therapeutics Inc.
KPTIHealthcare|Biotechnology|US
$0.05
-0.01 (-8.65%)
Cash / Share
$2.25
Financials
Financial Snapshot
Market Cap
$1.2M
Enterprise Value
$162.2M
Revenue (TTM)
$146.6M
Net Income (TTM)
-$224.7M
Cash & Investments
$65.1M
Net Cash
-$150.8M
Free Cash Flow (TTM)
-$65.3M
Operating CF (TTM)
-$65.3M
Debt/Equity
-0.65
Cash Runway & Burn Rate
Cash on Hand
$65.1M
Quarterly Burn
$16.3M
Monthly Burn
$5.4M
Est. Runway
~4.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $129.6M | $146.5M | $328.2M | $262.0M | $249.2M | $228.6M | $278.0M | $191.4M | $108.7M | $63.7M | $65.1M | |
| Operating Cash Flow | -$84.4M | -$73.7M | -$159.1M | -$190.8M | -$160.2M | -$107.1M | -$149.6M | -$92.7M | -$127.5M | -$75.4M | -$65.3M | |
| Free Cash Flow | -$84.5M | -$73.8M | -$161.5M | -$191.0M | -$160.4M | -$112.8M | -$149.7M | -$92.7M | -$127.6M | -$75.4M | -$65.3M | |
| Capital Expenditure | -$70.0K | -$62.0K | -$2.4M | -$206.0K | -$145.0K | -$5.7M | -$118.0K | $0.00 | -$142.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $51.2M | $75.7M | $316.1M | $124.3M | $172.1M | $73.6M | $193.7M | $1.1M | $41.6M | $30.0M | $78.6M |
R&D Spending
R&D (TTM)
$121.9M
R&D Intensity
83.2%
R&D Growth vs Prior
-2.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.0K | $1.6M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M | $146.6M | |
| R&D Expense | $86.9M | $107.3M | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | $125.6M | $121.9M | |
| R&D % of Revenue | 56453.2% | 6683.7% | 531.9% | 299.2% | 139.5% | 76.7% | 94.6% | 95.0% | 98.6% | 86.0% | 83.2% | |
| SG&A | $23.9M | $24.9M | $48.8M | $105.4M | $126.4M | $143.8M | $145.4M | $131.9M | $115.4M | $105.2M | $102.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.0K | $1.6M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M | $146.6M | |
| Cost of Revenue | $86.9M | $107.3M | $161.4M | $2.4M | $2.7M | $3.4M | $5.2M | $4.9M | $6.0M | $5.9M | $6.0M | |
| Gross Profit | -$86.8M | -$105.7M | -$131.0M | $38.5M | $105.4M | $206.4M | $151.9M | $141.1M | $139.2M | $140.1M | $140.6M | |
| R&D | $86.9M | $107.3M | $161.4M | $122.3M | $150.8M | $160.8M | $148.7M | $138.8M | $143.2M | $125.6M | $121.9M | |
| SG&A | $23.9M | $24.9M | $48.8M | $105.4M | $126.4M | $143.8M | $145.4M | $131.9M | $115.4M | $105.2M | $102.0M | |
| Operating Income | -$110.7M | -$130.5M | -$179.9M | -$189.3M | -$171.8M | -$98.3M | -$142.2M | -$129.5M | -$119.4M | -$90.7M | -$82.3M | |
| Interest Expense | $0.00 | $0.00 | $2.5M | $15.6M | $27.1M | $26.0M | $25.0M | $23.8M | $37.4M | $45.8M | $49.3M | |
| Pretax Income | -$109.4M | -$128.9M | -$178.4M | -$199.6M | -$196.0M | -$123.8M | -$164.9M | -$142.8M | -$76.4M | -$196.0M | -$224.8M | |
| Net Income | -$109.6M | -$129.0M | -$178.4M | -$199.6M | -$196.3M | -$124.1M | -$165.3M | -$143.1M | -$76.4M | -$196.0M | -$224.7M | |
| EPS (Diluted) | -43.80 | -42.15 | -47.11 | -48.32 | -40.87 | -24.75 | -30.28 | -18.79 | -9.41 | -17.93 | -13.07 | |
| EBITDA | -$108.7M | -$128.2M | -$175.2M | -$182.9M | -$167.9M | -$97.0M | -$139.3M | -$118.4M | -$38.6M | -$149.9M | -$175.9M | |
| Shares Out. (M) | 2.50 | 3.06 | 3.79 | 4.13 | 4.80 | 5.01 | 5.46 | 7.61 | 8.12 | 10.93 | 28.94 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.7M | $69.0M | $118.0M | $128.9M | $85.9M | $190.5M | $135.2M | $52.2M | $62.5M | $60.5M | $55.0M | |
| Short-Term Investments | $79.9M | $77.5M | $210.2M | $133.1M | $163.3M | $38.2M | $142.8M | $139.2M | $46.2M | $3.2M | $10.1M | |
| Total Current Assets | $131.6M | $148.4M | $334.6M | $278.6M | $276.5M | $275.6M | $350.2M | $233.9M | $156.5M | $103.1M | $106.4M | |
| Total Assets | $180.4M | $180.3M | $341.2M | $295.0M | $313.1M | $305.3M | $358.2M | $240.4M | $164.4M | $108.4M | $111.3M | |
| Total Current Liabilities | $16.5M | $49.5M | $46.9M | $46.4M | $60.2M | $73.7M | $65.9M | $69.5M | $92.3M | $92.1M | $134.2M | |
| Long-Term Debt | $0.00 | $0.00 | $102.7M | $109.9M | $117.9M | $169.3M | $170.1M | $170.9M | $162.9M | $205.9M | $209.6M | |
| Total Liabilities | $18.1M | $50.8M | $158.0M | $245.2M | $262.5M | $385.0M | $374.8M | $376.6M | $350.4M | $401.3M | $441.5M | |
| Stockholders' Equity | $162.2M | $129.5M | $183.2M | $49.8M | $50.5M | -$79.7M | -$16.7M | -$136.2M | -$186.0M | -$292.9M | -$330.2M | |
| Retained Earnings | -$366.1M | -$495.3M | -$673.7M | -$873.3M | -$1.07B | -$1.18B | -$1.34B | -$1.49B | -$1.56B | -$1.76B | -$1.85B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$84.4M | -$73.7M | -$159.1M | -$190.8M | -$160.2M | -$107.1M | -$149.6M | -$92.7M | -$127.5M | -$75.4M | -$65.3M | |
| Capital Expenditure | -$70.0K | -$62.0K | -$2.4M | -$206.0K | -$145.0K | -$5.7M | -$118.0K | $0.00 | -$142.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$84.5M | -$73.8M | -$161.5M | -$191.0M | -$160.4M | -$112.8M | -$149.7M | -$92.7M | -$127.6M | -$75.4M | -$65.3M | |
| Investing Cash Flow | $24.6M | $17.1M | -$107.7M | $78.5M | -$53.7M | $141.8M | -$104.3M | $7.9M | $95.5M | $43.4M | $3.0M | |
| Financing Cash Flow | $51.2M | $75.7M | $316.1M | $124.3M | $172.1M | $73.6M | $193.7M | $1.1M | $41.6M | $30.0M | $78.6M | |
| Issuance of Stock | $50.6M | $74.9M | $145.7M | $46.2M | $161.8M | $9.9M | $189.8M | $1.1M | $1.5M | $9.5M | $60.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $166.9M | $0.00 | $0.00 | $60.0M | $0.00 | $0.00 | $83.3M | $20.5M | $20.5M | |
| Stock Based Comp. | $22.3M | $20.4M | $17.3M | $15.3M | $24.4M | $29.8M | $35.4M | $21.7M | $18.4M | $14.1M | $11.6M | |
| Net Change in Cash | -$8.7M | $19.3M | $49.3M | $12.0M | -$41.6M | $108.3M | -$60.6M | -$83.7M | $9.6M | -$1.9M | $16.3M |
Dilution Tracker
Shares outstanding grew 127.7% over 5 years — significant dilution
Shares Outstanding
23M
5-Year Share Growth
+127.7%
Stock Issuance (TTM)
$60.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2.50 | 3.06 | 3.79 | 4.13 | 4.80 | 5.01 | 5.46 | 7.61 | 8.12 | 10.93 | 28.94 | |
| Change vs Prior % | — | 22.3% | 23.7% | 9.1% | 16.3% | 4.4% | 8.8% | 39.5% | 6.7% | 34.6% | 164.6% | |
| Stock Issuance | $50.6M | $74.9M | $145.7M | $46.2M | $161.8M | $9.9M | $189.8M | $1.1M | $1.5M | $9.5M | $60.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $22.3M | $20.4M | $17.3M | $15.3M | $24.4M | $29.8M | $35.4M | $21.7M | $18.4M | $14.1M | $11.6M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -56353.2% | -6583.7% | -431.9% | 94.1% | 97.5% | 98.4% | 96.7% | 96.6% | 95.9% | 95.9% | 95.9% | |
| Operating Margin % | -71903.9% | -8133.2% | -593.0% | -462.9% | -159.0% | -46.8% | -90.5% | -88.7% | -82.2% | -62.1% | -56.2% | |
| Net Margin % | -71153.9% | -8036.4% | -588.1% | -488.1% | -181.6% | -59.1% | -105.2% | -98.0% | -52.6% | -134.2% | -153.3% | |
| EBITDA Margin % | -70598.1% | -7988.0% | -577.4% | -447.3% | -155.3% | -46.2% | -88.7% | -81.1% | -26.6% | -102.6% | -119.9% | |
| FCF Margin % | -54844.8% | -4596.8% | -532.3% | -467.1% | -148.4% | -53.8% | -95.3% | -63.5% | -87.9% | -51.6% | -44.6% | |
| ROE % | -67.5% | -99.6% | -97.4% | -401.0% | -388.3% | 155.7% | 992.4% | 105.1% | 41.1% | 66.9% | 77.6% | |
| ROA % | -60.7% | -71.5% | -52.3% | -67.7% | -62.7% | -40.6% | -46.1% | -59.5% | -46.5% | -180.8% | -201.9% | |
| ROIC % | -67.6% | -99.8% | -61.1% | -75.6% | -67.5% | -42.0% | -48.2% | -74.3% | -123.1% | -236.6% | 376.9% | |
| R&D / Revenue % | 56453.2% | 6683.7% | 531.9% | 299.2% | 139.5% | 76.7% | 94.6% | 95.0% | 98.6% | 86.0% | 83.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -38.4% | 942.2% | 1790.1% | 34.8% | 164.3% | 94.1% | -25.1% | -7.0% | -0.5% | 0.6% | |
| Gross Profit | 11.0% | -21.8% | -24.0% | 129.4% | 173.8% | 95.9% | -26.4% | -7.1% | -1.3% | 0.6% | |
| Operating Income | 7.0% | -17.9% | -37.8% | -5.2% | 9.2% | 42.8% | -44.7% | 8.9% | 7.8% | 24.1% | |
| Net Income | 7.3% | -17.7% | -38.3% | -11.9% | 1.7% | 36.8% | -33.2% | 13.4% | 46.6% | -156.5% | |
| EPS (Diluted) | 12.0% | 3.8% | -11.8% | -2.6% | 15.4% | 39.4% | -22.3% | 37.9% | 49.9% | -90.5% | |
| Operating Cash Flow | 10.3% | 12.6% | -115.8% | -19.9% | 16.0% | 33.2% | -39.6% | 38.0% | -37.5% | 40.9% | |
| Free Cash Flow | 11.5% | 12.6% | -118.9% | -18.3% | 16.0% | 29.6% | -32.7% | 38.0% | -37.6% | 40.9% | |
| R&D Expense | -11.1% | 23.4% | 50.4% | -24.2% | 23.3% | 6.6% | -7.6% | -6.7% | 3.2% | -12.3% | |
| SG&A Expense | 11.0% | 3.9% | 96.4% | 115.8% | 19.9% | 13.8% | 1.1% | -9.3% | -12.5% | -8.9% | |
| Total Assets | -16.3% | -0.1% | 89.2% | -13.5% | 6.1% | -2.5% | 17.3% | -32.9% | -31.6% | -34.1% | |
| Book Value / Share | -22.4% | -34.8% | 14.3% | -75.1% | -12.7% | -251.0% | 80.8% | -486.2% | -28.0% | -17.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 21.5% | 5.2% | 37.7% | -0.8% | -1.1% | 9.9% | 20.1% | |
| Diluted Shares | 5.3% | 22.3% | 23.7% | 9.1% | 16.3% | 4.4% | 8.8% | 39.5% | 6.7% | 34.6% |
Valuation
P/E (TTM)At Loss
P/S0.01
10Y Low / Med / High0.55 / 10.30 / 2287.93
P/B-0.00
10Y Low / Med / High2.17 / 3.40 / 23.84
EV/EBITDAAt Loss
EV/Revenue1.11
10Y Low / Med / High1.48 / 10.72 / 1965.44
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$2.25
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3.22 | -3.41 | -2.98 | -5.94 | -5.67 | -3.89 | -1.68 | -0.69 | -1.08 | -0.41 | -0.00 | |
| P/S Ratio | 2287.93 | 274.25 | 17.53 | 29.01 | 10.30 | 2.30 | 1.77 | 0.68 | 0.57 | 0.55 | 0.01 | |
| P/B Ratio | 2.17 | 3.40 | 2.90 | 23.84 | 22.04 | -6.06 | -16.71 | -0.73 | -0.44 | -0.27 | -0.00 | |
| EV/EBITDA | -2.78 | -2.90 | -2.95 | -6.46 | -6.90 | -4.88 | -2.31 | -1.89 | -5.55 | -1.69 | -0.92 | |
| EV/Revenue | 1965.44 | 231.27 | 17.02 | 28.91 | 10.72 | 2.25 | 2.05 | 1.53 | 1.48 | 1.74 | 1.11 |
Analyst Estimates & Quality
Altman Z-Score
-27.45
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $136.3M | $172.7M | $332.3M |
| Net Income | -$50.3M | -$20.5M | -$4.1M |
| EPS | $-4.61 | $-1.79 | $-1.07 |
| # Analysts (EPS) | 2 | 2 | 2 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| License And Other | $31.9M | $111.4M | — | — | — | — |
| Product | $76.2M | $98.4M | — | — | — | — |
| License and Service | — | — | $15.7M | $24.4M | $28.0M | $28.3M |
| Royalty | — | — | $300.0K | $1.5M | — | — |
| License | — | — | — | $3.5M | — | — |
| Health Care, Other | — | — | — | — | $2.7M | $572.0K |
By Geography
| Segment | 2020 |
|---|---|
| CANADA | $5.0M |